Sex-dependent GOAL screening performance in adults at risk for obstructive sleep apnea R.L.M. Duarte; F.J. Magalhães-da-Silveira; D. Gozal;

Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study F. Barata; H. Queiroga; E. Teixeira; T. Almodovar; M. Soares; B. Parente; J.C. Mellidez; P. Alves; A. Antunes;